Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

Discover why Vertex Pharmaceuticals outperforms amid biotech sector decline. Explore growth drivers, risks, and the ...

PGIM Jennison Health Sciences Fund released its first quarter 2025 investor letter. A copy of the letter can be downloaded ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

The stock's fall snapped a three-day winning streak.

Vertex Pharmaceuticals Incorporated remains a top Buy with a strong cystic fibrosis franchise, innovative pipeline, and cell therapies. Click for my VRTX update.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 10 biotech stocks screaming a buy. On June 17, RBC Capital reiterated a Sector Perform rating on the stock but cut the price target ...

Vertex Pharmaceuticals VRTX announced that the European Commission has approved Alyftrek ...

VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to ...